Search
Blog Post
Esophageal Cancer Q&A with Dr. Fountzilas
… Esophageal Cancer Q&A with Dr. Fountzilas April is Esophageal Cancer Awareness Month. Here, Christos Fountzilas, MD , Associate Professor of Oncology and … April is Esophageal Cancer Awareness Month. Here, Christos Fountzilas, MD , Associate Professor of Oncology and …
Blog Post
Can you have liver cancer and not know it?
… that is significantly damaged,” according to Christos Fountzilas, MD, FACP , Assistant Professor of GI Medical … fluke is a common cause of liver cancer, according to Dr. Fountzilas. More commonly, however, tumors or cancer in the … liver cancer. Learn More How to avoid liver cancer Dr. Fountzilas recommends taking measures to avoid organ damage …
Blog Post
New options for KRAS-associated cancers available at Roswell Park
… — or who develop resistance — to the drug,” says Christos Fountzilas, MD, FACP, Associate Professor of Oncology and … in my trial takes a different approach,” explains Dr. Fountzilas. “It binds to the KRAS molecule and breaks it … lung, or colon cancer for KRAS mutations,” says Dr. Fountzilas. “We used to test people for KRAS because having …
Clinical Trial
A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor…
… (FGFR)-altered, Chemotherapy- and FGFR Inhibitor… III Fountzilas, Christos This study is a Phase III, Randomized, …
Clinical Trial
A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2 Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or…
… Gastroesophageal Junction (GEJ), Esophageal, or… I Fountzilas, Christos This is a Phase 1, Open-Label, Dose …
Blog Post
What's New in Pancreatic Cancer Research?
… to treat it. “We should always have hope,” says Christos Fountzilas, MD, FACP , Department of Medical Oncology at … existing therapy. Some of the latest developments that Dr. Fountzilas considers exciting are new agents that target the … efforts from basic and clinical cancer researchers, Dr. Fountzilas explains. “Blocking a single pathway is not …
Clinical Trial
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors
… with Locally Advanced or Metastatic Solid Tumors II Fountzilas, Christos This is a proof-of-concept study …
Clinical Trial
A Phase I Study of Trifluridine/ Tipiracil plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced Cancers
… Polymerase Inhibitor Talazoparib in Advanced Cancers I Fountzilas, Christos This phase I trial investigates the side …
Blog Post
Can a commonly prescribed blood pressure drug improve survival for patients with esophageal cancer?
… and radiation in those patients,” says Christos Fountzilas, MD, FACP , Co-Leader of the Gastrointestinal … Early Phase Clinical Trials Program at Roswell Park. Dr. Fountzilas was co-author of an article in the journal Lancet … cancer.” 04/03/2023 - 12:29 Esophageal Cancer Q&A with Dr. Fountzilas New immunotherapy-based treatments for esophageal …
Blog Post
Burning questions about soothing acid reflux
… (NIHDDK) 11/28/2022 - 10:01 Esophageal Cancer Q&A with Dr. Fountzilas Gastroesophageal junction cancer: Rick's story …